In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU reveals proposals on pharma in TTIP talks

This article was originally published in Scrip

Executive Summary

The European Commission has released a number of texts laying out the EU's proposals on specific issues, including pharmaceutical and medical device regulation, that are under discussion with the US government as part of the negotiations on the Transatlantic Trade and Investment Partnership (TTIP). The commission says this is the first time it has made such proposals public during bilateral trade talks, and that this "reflects its commitment to greater transparency in the negotiations".

You may also be interested in...

Coronavirus Notebook: A UK Catapult, A Russian Vaccine, And A Cuban Therapy

The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.

‘Onshoring’ Not The Way To Tackle UK Coronavirus-Related Demand

A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.

EMA’s Choice For New Head Impresses EU Parliamentarians

The European Medicines Agency is preparing to appoint its new executive director after nominee Emer Cooke presented her case to the European Parliament. 

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts